Nachrichten zur Guerbet S.A. Aktie

First-half 2023 revenue      ...…

Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer...…

Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development...…

Das Instrument 4G8 FR0000032526 GUERBET SA INH. EO 1 EQUITY wird ex Dividende/Zinsen gehandelt am…

Q1 2023 RevenueQuarterly activity...…

2022 annual results...…

First dosage administered at the Hospital of the University of Pennsylvania following FDA approval Elucirem™ has the highest relaxivity compared…

2022 revenue...…

2023 Strategic Priorities...…

Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under…

Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved novel new drug, Elucirem™ Announcing Guerbet Research…

Guerbet announces a change in governance for its Artificial Intelligence projects...…

Revenue on September 30, 2022...…